$Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma$

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

Background: To apply our preclinical findings of cytotoxic synergy with the combination of estramustine phosphate (EP) and docetaxel as the basis of treatment of hormone refractory metastatic prostate cancer in man. To determine the optimal dosage and the toxicities of these two agents for future tr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 1999-01, Vol.10 (1), p.33-38
Hauptverfasser:	Kreis, W., Budman, D. R., Fetten, J., Gonzales, A. L., Barile, B., Vinciguerra, V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Neoplasms - secondary Chemotherapy Docetaxel Dose-Response Relationship, Drug Drug Administration Schedule estramustine Estramustine - administration & dosage Humans Lung Neoplasms - secondary Male Medical sciences Middle Aged Paclitaxel - administration & dosage Paclitaxel - analogs & derivatives Pharmacology. Drug treatments phase I Prognosis prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Survival Rate Taxoids Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!